glutathione myelin sheath repair Manage Autoimmune Disease with Mikael Simons: Myelin Regeneration |

Regulatory Timeline and Expectations CagriSema (Cagrilintide + Semaglutide): FDA review ongoing for obesity indication European Medicines Agency (EMA) submission completed Potential approval expected in late 2026 or early 2027 Would represent first approved amylin analogue combination therapy Cagrilintide Monotherapy: Less likely to be pursued as standalone therapy Combination approaches show superior efficacy May remain primarily a research tool Emerging Research Questions Key questions driving current research include: Optimal combination partners Beyond semaglutide, which peptides pair best with cagrilintide

In addition, REW enhanced the transport across cell layers and mucosal barriers upon intranasal delivery in mice, which was also the case for an influenza A HA-fused IgG1 Fc-fusion that was shown to protect against a deadly dose of the virus in the presence of adjuvant

Unsure which to choose

Taking vitamin B12 supplements

Third-party testing provides an extra layer of security

Videla LA, Hernandez-Rodas MC, Metherel AH, Valenzuela R